Brought to you by 
Servier licenses Cortex's Ampakine in Europe, Asia; concluded; later terminated
16 Jun 2011
Executive Summary
Privately held French pharmaceutical company Servier has licensed exclusive rights in Europe, Asia, Middle East, and parts of South America to Cortex Pharmaceuticals' (neurological and psychiatric disorder therapeutics) Ampakine brain receptor modulation technology for treating aging and neurodegenerative diseases marked by a decline in cognitive performance.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Servier licenses Cortex's Ampakine in Europe, Asia; concluded; later terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice